Novel metabolic drugs for the management of type 2 diabetes

Practical Diabetes International

Volumn 23, Issue 3, 2006, Pages 129-134

  Barnett, Anthony H ^a   Bellary, Srikanth ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Abdominal obesity; Future; Metaglidasen; Muraglitazar; PPAR; Rimonabant; Tesaglitazar; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GW 501516; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; MBX 2044; METAGLIDASEN; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TESAGLITAZAR; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTHRALGIA; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; EDEMA; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; LIVER TOXICITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; WEIGHT GAIN;

EID: 33751028473     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.920     Document Type: Review

References (42)

1. Diabetes UK press release. Diabetes affects record numbers. Accessed at http://www.diabetes.org.uk/news/sept05/record.htm
2. The World Health Organization. Global Strategy on Diet, Physical Activity and Health: Obesity and Overweight. Accessed at http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/
3. IDF Clinical Guidelines Task Force. Global guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
4. National Institute for Clinical Excellence. Management of type 2 diabetes: management of blood glucose. London: National Institute for Clinical Excellence, Sept 2002.
5. Dungan K, Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes 2005; 2: 56-62.
6. Brower V. Like a snake in the grass. EMBO reports 2004; 5: 555-558.
7. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Peptides 2005; 128: 117-124.
8. Demuth HU, McIntosh CH, Pedersen RA. Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751: 33-44.
9. Cheng PTW, Mukherjee R. PPARs as targets for metabolic and cardiovascular diseases. Mini Rev Med Chem 2005; 5: 741-753.
10. Rosenstock J, Flores-Lozano F, Schwartz S, et al. MBX-102: A novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with Type 2 diabetes (T2DM) on concomitant insulin therapy. Abs 44-OR, ADA, 65th Annual Scientific Sessions, San Diego, California, 2005.
11. ll Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
12. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
13. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
14. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44: 2210-2219.
15. Home PD, Pocock SJ, Beck Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48: 1726-1735.
16. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive). Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 2004; 27: 1647-1653.
17. Food and Drug Administration. Withdrawal of troglitazone and cisapride. JAMA 2000; 283: 2228.
18. Fatehi Hassanabad Z, Chan CB. Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic β-cell function. Nutrition & Metabolism 2005; 2: 1.
19. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised clinical trial. Lancet 2005; 366: 1279-1289.
20. Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Austr 2004; 181: 536-539.
21. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.
22. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: A review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy and tolerability. Diab Tech & Therap 2004; 6: 850-863.
23. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) coagonism: the bezafibrate lessons. Cardiovasc Diabetol 2005; 4: Epub.
24. Saad MF, Greco S, Osei K, & et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. A 12 week, double blind, placebo-controlled dose ranging study with an open pioglitazone arm. Diabetes Care 2004; 27: 1324-1329.
25. Friederich R, Viraswami-Appanna K, Rubin CJ. Glycemic efficacy and tolerability of muraglitazar, a novel dual peroxisome proliferator activated receptor-alpha/gamma agonist, in drug naïve patients with type 2 diabetes: A randomized, double blind, placebo controlled trial. Endocr Pract 2005; 11: 27; Abs 866.
26. Friederich R, Viraswami-Appanna K, Rubin CJ. Effects of long term therapy (2-year with muraglitazar, a novel dual PPAR αγ agonist, on diabetic dyslipidemia in patients with type 2 diabetes: a double blind, randomized, parallel group study. Abs 967-P, ADA, 65th Annual Scientific Sessions, San Diego, California, 2005.
27. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA express. Published online 20 October, 2005.
28. Goldstein BJ, Rosenstock J, Anzalone D, et al. Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes. Abs 83-OR, ADA, 65th Annual Scientific Sessions, San Diego, California, 2005.
29. Adapted from http://www.biocarta.com/pathfiles/h_pparPathway.asp
30. Muscat GE, Dressel U. Cardiovascular disease and PPAR delta: targeting the risk factors. Curr Opin Investig Drugs 2005; 6: 887-894.
31. McLaughlin T, Allison G, Abbassi F, et al. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight and obese individuals. Metabolism 2004; 53: 495-499.
32. Wahrenberg H, Hertel K, Leijonhufvud BM, et al. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 2005; 330: 1363-1364.
33. Lichtman AH, Cravatt BF. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005; 115: 1130-1133.
34. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet induced obesity. J Clin Invest 2005; 115: 1298-1305.
35. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
36. Cota D, Marsicano G, Lutz B, et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003; 27: 289-301.
37. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005; 365: 1363-1364.
38. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep (ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29: 183-187.
39. ADA Late breaking symposium. New drug treats multiple problems of people with type 2 diabetes. Rimonabant lowers blood glucose and reduces weight, waist size and lipid problems. ADA, 65th Annual Scientific Sessions, San Diego, California, 2005.
40. Rosenstock J. The potential of rimonabant in prediabetes: pooled 1-year results from the RIO-Lipids, RIO-Europe and RIO-North America studies. Abs 13-LB, ADA, 65th Annual Scientific Sessions, San Diego, California, 2005.
41. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-468.
42. Hutton B, Ferguson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocalorific diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-1468.